Greenland J R, Sun H, Calabrese D, Chong T, Singer J P, Kukreja J, Hays S R, Golden J A, Caughey G H, Venstrom J M, Rajalingam R
Medical Service, Veterans Affairs Medical Center, San Francisco, CA.
Department of Medicine, University of California, San Francisco, CA.
Am J Transplant. 2017 Aug;17(8):2192-2199. doi: 10.1111/ajt.14295. Epub 2017 May 11.
Chronic lung allograft dysfunction (CLAD) is linked to rejection and limits survival following lung transplantation. HLA-Bw4 recipients of HLA-Bw6 grafts have enhanced host-versus-graft (HVG) natural killer (NK) cell activity mediated by killer cell immunoglobulin-like receptor (KIR)3DL1 ligand. Because NK cells may promote tolerance by depleting antigen-presenting cells, we hypothesized improved outcomes for HLA-Bw4 recipients of HLA-Bw6 grafts. We evaluated differences in acute cellular rejection and CLAD-free survival across 252 KIR3DL1+ recipients from University of California, San Francisco (UCSF). For validation, we assessed survival and freedom from bronchiolitis obliterans syndrome (BOS), retransplantation, or death in 12 845 non-KIR typed recipients from the United Network for Organ Sharing (UNOS) registry. Cox proportional hazards models were adjusted for age, gender, ethnicity, transplant type, and HLA mismatching. HVG-capable subjects in the UCSF cohort had a decreased risk of CLAD or death (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.36-0.88) and decreased early lymphocytic bronchitis. The HVG effect was not significant in subjects with genotypes predicting low KIR3DL1 expression. In the UNOS cohort, HVG-capable subjects had a decreased risk of BOS, retransplant, or death (HR 0.95, 95% CI 0.91-0.99). Survival improved with the higher-affinity Bw4-80I ligand and in Bw4 homozygotes. Improved outcomes in HVG-capable recipients are consistent with a protective NK cell role. Augmentation of NK activity could supplement current immunosuppression techniques.
慢性肺移植功能障碍(CLAD)与排斥反应相关,并限制肺移植后的生存率。接受HLA - Bw6移植物的HLA - Bw4受者具有增强的宿主抗移植物(HVG)自然杀伤(NK)细胞活性,该活性由杀伤细胞免疫球蛋白样受体(KIR)3DL1配体介导。由于NK细胞可能通过消耗抗原呈递细胞来促进免疫耐受,我们推测接受HLA - Bw6移植物的HLA - Bw4受者会有更好的预后。我们评估了来自加利福尼亚大学旧金山分校(UCSF)的252名KIR3DL1 +受者在急性细胞排斥反应和无CLAD生存率方面的差异。为了进行验证,我们评估了器官共享联合网络(UNOS)登记处12845名未进行KIR分型的受者的生存率以及无闭塞性细支气管炎综合征(BOS)、再次移植或死亡的情况。Cox比例风险模型根据年龄、性别、种族、移植类型和HLA错配情况进行了调整。UCSF队列中具有HVG能力的受试者发生CLAD或死亡的风险降低(风险比[HR] 0.57,95%置信区间[CI] 0.36 - 0.88),早期淋巴细胞性支气管炎减少。在预测KIR3DL1低表达的基因型受试者中,HVG效应不显著。在UNOS队列中,具有HVG能力的受试者发生BOS、再次移植或死亡的风险降低(HR 0.95,95% CI 0.91 - 0.99)。具有更高亲和力的Bw4 - 80I配体以及Bw4纯合子的生存率有所提高。具有HVG能力的受者预后改善与NK细胞的保护作用一致。增强NK活性可以补充当前的免疫抑制技术。